The outcome of CyberKnife treatment for primary or metastatic malignant lung tumors

Chun Shu Lin, Wei Chou Chang, Hsuan Hwai Lin, Wen Yen Huang, Hsing Lung Chao, Chang Ming Chen, Yu Fu Su, Kuen Tze Lin, Jang Chun Lin, Yee Min Jen

Research output: Contribution to journalArticlepeer-review


Background: To analyze the local control of malignant lung tumors and survival of nonsmall cell lung cancer (NSCLC) patients after stereotactic ablative radiotherapy with CyberKnife. Materials and Methods: Patients with malignant lung tumors treated by CyberKnife between July 2007 and October 2010 at our institute were retrospectively reviewed. A total of 55 patients with 110 malignant lung tumors were included. There were 32 men and 23 women, and the median age was 67 years. There were 11 early-stage NSCLCs, while the other 44 patients with 99 lesions were metastatic lung tumors. The median gross tumor volume was 13.3 ml. Radiotherapy schedules include 40-60 Gy in 4-5 fractions, 45-60 Gy in 3 fractions and 30 Gy in 1 fraction. Results: The median follow-up time for patients alive was 34 months. The local control rates for all tumors were 96% at 1-year and 80% at 2 years. Univariate analysis demonstrated that target volume was important for local control. Biologically equivalent dose (BED) ≥100 Gy provided significantly higher chance to achieve a complete response than BED <100 Gy. The disease-specific survival rates for early-stage NSCLC were 80% at 1-year and 60% at 2 years. Treatment related complications were acceptable. No grade 2-5 adverse events were noted. Conclusions: CyberKnife can be used for NSCLC and metastatic lung tumors, either peripheral or central location, with good local control and acceptable side-effects.

Original languageEnglish
Pages (from-to)145-151
Number of pages7
JournalJournal of Medical Sciences (Taiwan)
Issue number4
Publication statusPublished - 2014
Externally publishedYes


  • CyberKnife
  • Lung cancer
  • Lung metastases
  • Stereotactic ablative radiotherapy
  • Stereotactic body radiotherapy

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'The outcome of CyberKnife treatment for primary or metastatic malignant lung tumors'. Together they form a unique fingerprint.

Cite this